Tag
Anthropic's IPO filing tempers its ambitious claims about AI revolutionizing biology and drug discovery, acknowledging its lack of lab experience, regulatory hurdles, and the long timelines of drug development while still positioning biotech discovery as a core part of its business.
A tech figure (@gabriel1) argues that AI will soon cure most diseases, and warns that slow regulatory approval could cost billions of years of life, urging regulators to staff up and speed up approvals.
Biohub, the U.S. Department of Energy, the NIH, Google DeepMind, Isomorphic Labs, and Meta jointly committed $1.8 billion to generate AI-ready open biological datasets, the largest coordinated effort to date to enable predictive AI models of biology and a 'virtual cell'.
Biohub, the U.S. Department of Energy, NIH, Google DeepMind, Isomorphic Labs, and Meta announced a $1.8 billion expansion of the Virtual Biology Initiative to generate open, AI-ready biological datasets for building predictive models of biology and accelerating disease research.
Microsoft Research introduces Quine, an early-stage AI system that creates a multimodal world model of biology to help scientists computationally explore complex hypotheses and prioritize experiments.
NVIDIA, Google DeepMind, and other organizations have released predicted 3D structures for over 2,800 viral proteins using AlphaFold2 and NVIDIA BioNeMo tools to help researchers prepare for future pandemics, making the data openly available.
Anthropic announced a Claude-led discovery of a molecular machine that may represent a new gene editing mechanism, emphasizing AI's potential to rapidly advance biological research from weak to superhuman levels.
Anthropic has established a wet biology lab in the Bay Area to use its AI models for physical experiments, focusing on fundamental biology, while navigating partnerships and safety concerns in the AI-driven biotech space.
A fireside chat at TechCrunch Disrupt 2026 will discuss how AI is advancing de-extinction and conservation, featuring Ben Lamm of Colossal Biosciences.
Scientists have used AI to design novel bacteriophages, raising concerns about biosecurity and the pace of regulation for AI-enabled biotechnology.
Researchers used large genome models Evo 1 and Evo 2 to design new bacteriophage genomes, producing viruses with distinct features challenging to evolve naturally, raising questions about potential future design of vertebrate-targeting viruses.
This article highlights a major conceptual novelty and infrastructure breakthrough in generative biology, likely involving advanced AI models for biological design and discovery.
A cloud lab for biology allows running experiments via API in minutes, eliminating the need for expensive automation engineers and long setup times, enabling solo founders to conduct thousands of drug screens quickly.
Nicole Fitzgerald announces Tacit Labs, a new applied research lab at the intersection of AI and biology, with investment from Every.
The article highlights research from the Weissman lab at MIT, praising their recent contributions.
Three major AI labs — Anthropic, OpenAI, and Amazon — have made significant moves into biology this month, signaling a major industry shift toward AI-driven life sciences as the next frontier of value creation.
GPT-5 demonstrated a 40% reduction in cell-free protein synthesis (CFPS) costs through closed-loop experimentation with Ginkgo Bioworks' cloud laboratory, testing over 36,000 unique reaction compositions and achieving novel, robust formulations in just three rounds of optimization.
OpenAI demonstrates GPT-5's capability to accelerate biological research by autonomously optimizing a molecular cloning protocol in collaboration with Red Queen Bio, achieving a 79-fold improvement in cloning efficiency through novel enzymatic mechanisms. The work showcases AI's potential to support experimental iteration and empirical validation in wet lab settings while highlighting biosecurity considerations.
OpenAI collaborated with Retro Biosciences to develop GPT-4b micro, a specialized version of GPT-4o for protein engineering, achieving 50-fold higher expression of stem cell reprogramming markers with enhanced DNA damage repair capabilities. The findings have been validated across multiple donors and cell types, demonstrating AI's potential to accelerate life sciences research.